Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCXH-211 in Malignant Solid Tumors
NCT05539157Phase 1Terminated
- Sponsor
- Immorna
- Start
- Oct 2022
- Primary completion
- Apr 2023
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of JCXH-211 in malignant solid tumor (2 arms), sponsored by Immorna. Primary endpoints: Dose Limiting Toxicity at 29 days and Incidence of Adverse Events at 30 days. Started Oct 2022; status: terminated.
02
Drugs
JCXH-211
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT05539157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05539157.